In this study, we showed that LECT2 serves as a tumor suppressor in PDAC progression as follows: (1) LECT2 is downregulated in metastatic PDACs compared with the primary tumor, and its expression is negatively correlated with multiple clinical pathologic features and prognosis. This evidence concerns the gene LECT2 and neoplasm.